Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amubarvimab/romlusevimab - Brii Biosciences

Next Previous
Drug Profile

Amubarvimab/romlusevimab - Brii Biosciences

Alternative Names: Amubarvimab/romlusevimab combination - Brii Biosciences; BRII-196/BRII-198

Latest Information Update: 08 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Third People's Hospital of Shenzhen; Tsinghua University
  • Developer Brii Biosciences; National Institute of Allergy and Infectious Diseases; TSB Therapeutics (Beijing) CO.LTD
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 14 Jul 2023 National Institute of Allergy and Infectious Diseases completes a phase III trial in COVID-2019 infections (Combination therapy) in United Kingdom, Nigeria, Uganda, Singapore, Denmark, Spain, Switzerland, Greece, USA, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)
  • 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (IV) (NCT04518410)
  • 19 Feb 2023 Updated efficacy data from the phase II Activ-2 trial in COVID-19 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top